Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential versus concurrent cisplatin-based chemoradiotherapy for inoperable non-small cell lung cancer
NL-OMON22854Phase 3Active, not recruiting
- Sponsor
- N/A
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by N/A. Primary endpoints: Disease-free survival, Local control and 1 more. Started May 2003; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON22854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22854.